ALMR logo

Alamar Biosciences, Inc.

ALMR
Healthcare|Biotechnology|US
$28.05
+1.15 (+4.26%)
DCF Value
$22.60
Tangible Book / Share
$4.37
Cash / Share
$3.28

Financials

Financial Snapshot

Market Cap
$1.95B
Enterprise Value
$1.87B
Revenue (TTM)
—
Net Income (TTM)
—
Cash & Investments
—
Net Cash
—
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.14

R&D Spending

R&D (2025)
$37.5M
R&D Intensity
50.5%
R&D Growth vs Prior
—
MetricTrend2025
Revenue$74.2M
R&D Expense$37.5M
R&D % of Revenue50.5%
SG&A$35.6M

Income Statement

MetricTrend2025
Revenue$74.2M
Cost of Revenue$32.5M
Gross Profit$41.7M
R&D$37.5M
SG&A$35.6M
Operating Income-$31.3M
Interest Expense$401.0K
Pretax Income-$29.2M
Net Income-$29.8M
EPS (Diluted)-0.45
EBITDA-$24.9M
Shares Out. (M)66.52

Balance Sheet

MetricTrend2025
Cash & Equivalents$30.0M
Short-Term Investments$0.00
Total Current Assets$94.7M
Total Assets$140.0M
Total Current Liabilities$23.7M
Long-Term Debt$9.8M
Total Liabilities$298.9M
Stockholders' Equity-$159.0M
Retained Earnings-$168.8M

Cash Flow Statement

MetricTrend2025
Operating Cash Flow-$53.6M
Capital Expenditure-$6.4M
Free Cash Flow-$60.0M
Investing Cash Flow$46.2M
Financing Cash Flow$10.8M
Issuance of Stock$1.5M
Repurchase of Stock$0.00
Net Debt Issuance$10.0M
Stock Based Comp.$2.9M
Net Change in Cash$3.2M

Dilution Tracker

Shares Outstanding
69M
5-Year Share Growth
+0.0%
Stock Issuance (2025)
$1.5M
MetricTrend2025
Shares Out. (M)66.52
Stock Issuance$1.5M
Stock Repurchase$0.00
Stock Based Comp.$2.9M

Margins & Profitability

MetricTrend2025
Gross Margin %56.2%
Operating Margin %-42.2%
Net Margin %-40.2%
EBITDA Margin %-33.5%
FCF Margin %-80.8%
ROE %18.8%
ROA %-21.3%
ROIC %-26.5%
R&D / Revenue %50.5%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend20242025
Revenue
0.0%0.0%
Gross Profit
0.0%0.0%
Operating Income
0.0%0.0%
Net Income
0.0%0.0%
EPS (Diluted)
0.0%0.0%
Operating Cash Flow
0.0%0.0%
Free Cash Flow
0.0%0.0%
R&D Expense
0.0%0.0%
SG&A Expense
0.0%0.0%
Total Assets
0.0%-6.4%
Book Value / Share
0.0%0.0%
Debt
0.0%25.3%
Diluted Shares
0.0%0.0%

Valuation

P/E (TTM)At Loss
P/S21.87
P/B6.38
EV/EBITDAAt Loss
EV/Revenue20.98
P/FCFAt Loss

Intrinsic Value Models (per share)

DCF Value
$22.60
Tangible Book / Share
$4.37
Net Current Assets / Share
$3.51
Graham Net-Net
$2.83
Cash / Share
$3.28
MetricTrend2025
P/E Ratio-48.89
P/S Ratio19.72
P/B Ratio-9.21
EV/EBITDA-59.26
EV/Revenue19.87

Analyst Estimates & Quality

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$122.2M$167.8M$225.9M
Net Income-$79.3M-$55.5M-$28.1M
EPS$-1.19$-0.83$-0.42
# Analysts (EPS)223